Skip to content
Parakho

Alembic Pharmaceuticals Ltd

NSE APLLTDBSE 533573alembicpharmaceuticals.com

Q1 FY27, unaudited

Revenue
₹2,149.77 Cr
Profit after tax
₹172.36 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations2,149.77+25.66%7,344.90
Other income14.93+129.69%54.41
Total income2,164.70+26.06%7,399.31
Employee benefit expense473.94+12.10%1,731.93
Finance costs27.61+17.39%93.63
Depreciation & amortisation97.71+32.45%318.55
Total expenses1,943.23+27.29%6,638.62
Profit before tax221.47+16.23%693.71
Tax expense49.50+35.73%23.12
Profit after tax172.36+12.19%670.83
Total comprehensive income174.63+13.15%695.70
Earnings per share
Earnings per share, basic₹8.80₹34.33
Earnings per share, diluted₹8.80₹34.33

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Alembic Pharmaceuticals reported consolidated revenue growth of 26% year-on-year in Q1 FY27, driven by 37% growth in International Generics, 33% growth in the API business and 7% growth in the India branded business. Management raised its full-year FY27 revenue growth outlook to the mid-teen range from an earlier low double-digit expectation, citing stronger than expected US Generics performance including the launch of Bosutinib. EBITDA grew 21% year-on-year to Rs 348 crore with a 16% margin, while profit after tax grew 12% to Rs 173 crore reflecting a higher effective tax rate following migration to the new tax regime.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 92 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 08 Oct 2026.